Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011860 (type 2 diabetes)
 57,723 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The etiology of acute confusional state in elderly patients with type 2 diabetes mellitus is broad, including hypoglycemia or hyperglycemia, electrolyte imbalance as hyponatremia or hypercalcemia, cerebrovascular disease and drug intoxication among others. Herein, we present an 80-year-old female type 2 diabetic patient in an acute confusional state due to non-convulsive status epilepticus (NCSE). Timely electroencephalogram at an emergency department when available is the only tool for the diagnosis of NCSE when clinically suspected. All clinicians must consider the possibility of NCSE in the differential diagnosis of acute confusional patients when diagnosis is uncertain.
 ...
PMID:Acute confusional state in type 2 diabetic patient: non-convulsive status epilepticus. 1926 Sep 85

The aim of the study was to evaluate associations of emotional state and quality of life with lipid concentration, duration of the disease, and the way of treating the disease in males and females with type 2 diabetes mellitus. A total of 53 persons with type 2 diabetes mellitus (27 males and 26 females; mean age, 58.7+/-8.9 years) and 56 healthy persons (26 males and 30 females; mean age, 54.7+/-8.3 years) participated in the study. Emotional state was evaluated by means of Profile of Mood State and quality of life by means of WHO Brief Quality of Life Questionnaire. Emotional state and quality of life were significantly worse, tension-anxiety and fatigue-inertia were significantly higher, vigor-activity was significantly lower in male patients with type 2 diabetes mellitus than in healthy males. In females, no significant differences in emotional state and quality of life comparing type 2 diabetes mellitus group and controls were detected. In females with type 2 diabetes mellitus, emotional state and quality of life were significantly better, scores of tension-anxiety, depression dejection, anger-hostility, and fatigue-inertia were significantly lower, and score of vigor-activity was significantly higher than in males with type 2 diabetes mellitus. Some significant correlations were found. In males, vigor-activity correlated with total cholesterol level and negatively correlated with triglyceride level. In females, significant correlations were found between scores of emotional state (tension-anxiety, depression-dejection, confusion-bewilderment, and total score of emotional state) and lipid levels (total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels). There were no significant associations of emotional state and quality of life with duration of the disease in males and females with type 2 diabetes mellitus. No significant differences in emotional state and quality of life were found between males and females with type 2 diabetes mellitus, who were treated with oral antidiabetic preparations and insulin preparations.
 ...
PMID:[Associations of emotional state and quality of life with lipid concentration, duration of the disease, and the way of treating the disease in persons with type 2 diabetes mellitus]. 1928 98

The occurrence and impact of fructose in the American food supply has garnered much recent attention in the popular press as well as the scientific community. This paper provides an overview of a workshop cosponsored by the International Life Sciences Institute North America and the USDA, Agricultural Research Service, titled "State of the Science on Dietary Sweeteners Containing Fructose." Papers in the workshop addressed the chemical composition and properties of dietary sweeteners that contain fructose, the sources and amount of fructose in the American diet, and the metabolism of fructose in the human body. Further, the authors of each paper assessed the strength of the existing data linking dietary fructose intake and risk for overweight, metabolic syndrome, type 2 diabetes mellitus, cardiovascular disease, and other disorders. The assessment considered factors in study design, including the amount fed, the food form, the length of the study, the characteristics of the subjects, the specific methodology, and other potential confounders including diet. In addition to papers assessing the basic science of fructose, some papers also addressed consumer concern about sugars and fructose in the diet, the way fructose and other sugars are presented in the media, and the resulting confusion of consumers about fructose and other sugars in the diet. The purpose of the papers in the aggregate was to clarify what data exist about fructose and what the gaps are in the data and to help both scientists and consumers understand issues surrounding fructose in the food supply.
 ...
PMID:Dietary sweeteners containing fructose: overview of a workshop on the state of the science. 1938 22

This is a qualitative study report from a parent study that used a concurrent mixed methods design whose aim was to describe the transition and self-management experiences of patients diagnosed with type 2 diabetes mellitus (T2DM) and stage 3 chronic kidney disease (CKD). Six adult men and women recruited from outpatient clinics completed two focus group interviews. Discerned in the ethnographic analysis of interviews and field notes using ATLAS/ti was a pattern of Health Literacy Self-Management with two major threads: (a) transition experience to self-advocacy characterized as seeking useful resources and difficulties in resource use and (b) partnering with the health care provider (HCP) characterized as helpful messaging and messaging confusion. Self-management support includes a shared responsibility and developmental process by the patient and the HCP to achieve quality care. Description of behavioral factors and self-management processes provides a foundation for future study.
 ...
PMID:Health literacy self-management by patients with type 2 diabetes and stage 3 chronic kidney disease. 1939 53

Recent trials of intensive glycaemic control in patients with type 2 diabetes and its impact on cardiovascular disease have led to confusion and speculation amongst physicians. The Action to Control Cardiovascular Risk in Diabetes Study was terminated early because of a significant excess all-cause mortality in the intensively-treated group. Furthermore the ADVANCE and VADT trials did not demonstrate cardiovascular benefit with more intensive glycaemic control. Against this background, it is pertinent to re-visit and critically appraise the results of the PROactive study which examined the effects of the thiazolidinedione, pioglitazone, on cardiovascular end-points in a large, randomized, placebo-controlled clinical trial in type 2 diabetic patients with symptomatic disease. PROactive has been rightly criticized in the choice of its composite primary end-point which included a physician-driven as opposed to a disease-driven outcome, namely peripheral vascular re-vascularization. This was primarily responsible for the primary composite end-point not being achieved; whereas there was a significant beneficial impact on the major secondary end-point of death, non-fatal myocardial infarction and stroke. The results of PROactive have been supported by two subsequent studies examining the impact of pioglitazone on important surrogates of atherosclerosis, namely carotid intima/medial thickness (IMT) and coronary atheroma volume as delineated with intravascular ultrasound. The CHICAGO study demonstrated that IMT in type 2 diabetic patients treated with pioglitazone did not progress whereas those treated with glimepiride showed progression. In PERISCOPE atheroma volume progressed with glimepiride but did not with pioglitazone. This is exciting data pointing to the cardiovascular benefits of pioglitazone. In PROactive, CHICAGO and PERISCOPE there was a sustained effect of pioglitazone on glycaemic control and, in addition, beneficial effects in reducing triglycerides and increasing HDL-cholesterol beyond that seen with concomitant statin therapy. These findings strongly suggest that pioglitazone has an important place in the management of type 2 diabetes.
 ...
PMID:CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. 1974 48

The disorder now known as the "metabolic syndrome "was first recognized 50 years ago, but the use of various definitions led to confusion over its real nature. The metabolic syndrome is directly linked to android obesity, which reflects insulin resistance; it lies at the root of all associated risk factors and is a forerunner of type 2 diabetes. Screening is based on systematic waist measurement, taking ethnic origin into account. This pragmatic approach avoids the uncertainties generated by different definitions and is less restrictive than a simple diagnosis of the metabolic syndrome. Non drug treatment of android obesity is inexpensive and effective but may be difficult to apply, owing to a number of social issues.
 ...
PMID:[Obesity and the metabolic syndrome: a new epidemic]. 2012 Jan 60

Beta-cell deficit is the major pathological feature in type 1 and type 2 diabetes patients, and plays a key role in disease progression. In principle, beta-cell regeneration can occur by replication of pre-existing beta-cells, or by beta-cell neogenesis from stem/progenitors. Unfortunately, beta-cell replication is limited by the almost complete absence of beta-cells in patients with type 1 diabetes, and the increasing recognition that the beta-cell replicative capacity declines severely with age. Therefore, beta-cell neogenesis has received increasing interest. Many different cell types within the pancreas have been suggested as potential beta-cell stem/progenitor cells, but the data have been conflicting. In some cases, this may be due to different regeneration models. On the other hand, different results have been obtained with similar regeneration models, leading to confusion about the nature and existence of beta-cell neogenesis in adult animals. Here, we review the major candidates for adult regeneration pathways, and focus on the recent discovery that alpha-cells can function as a novel beta-cell progenitor. Of note, this is a pathway that appears to be unique to beta-cell neogenesis in the adult, as the embryonic pathway of beta-cell neogenesis does not proceed through a glucagon-positive intermediate. We conclude that beta-cell neogenesis from alpha-cells is a new pathway of potential therapeutic significance, making it of high importance to elucidate the molecular events in alpha- to beta-cell conversion.
 ...
PMID:Adult pancreatic alpha-cells: a new source of cells for beta-cell regeneration. 2106 Sep 71

The concepts of "cardiometabolic risk," "metabolic syndrome," and "risk stratification" overlap and relate to the atherogenic process and development of type 2 diabetes. There is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. With the objectives of clarifying these concepts and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group reviewed the evidence related to emerging cardiovascular risk factors and Canadian guideline recommendations in order to present a detailed analysis and consolidated approach to the identification and management of cardiometabolic risk. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. "Global cardiometabolic risk" is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider risk factors related to ethnicity in order to appropriately evaluate everyone in their diverse patient populations.
 ...
PMID:Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. 2145 57

With the objectives of clarifying the concepts related to "cardiometabolic risk," "metabolic syndrome" and "risk stratification" and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group presents an executive summary of a detailed analysis and position paper that offers a comprehensive and consolidated approach to the identification and management of cardiometabolic risk. The above concepts overlap and relate to the atherogenic process and development of type 2 diabetes. However, there is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. "Global cardiometabolic risk" is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider ethnicity-related risk factors in order to appropriately evaluate all individuals in their diverse patient populations.
 ...
PMID:Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). 2145 58

Intensive glycemic control using insulin therapy may be appropriate for many healthy older adults to reduce premature mortality and morbidity, improve quality of life, and reduce health care costs. However, frail elderly people are more prone to develop complications from hypoglycemia, such as confusion and dementia. Overall, older persons with type 2 diabetes mellitus are at greater risk of death from cardiovascular disease (CVD) than from intermittent hyperglycemia; therefore, diabetes management should always include CVD prevention and treatment in this patient population. Pharmacists can provide a comprehensive medication review with subsequent recommendations to individualize therapy based on medical and cognitive status. As part of the patient's health care team, pharmacists can provide continuity of care and communication with other members of the patient's health care team. In addition, pharmacists can act as educators and patient advocates and establish patient-specific goals to increase medication effectiveness, adherence to a medication regimen, and minimize the likelihood of adverse events.
 ...
PMID:Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team. 2165 41


<< Previous 1 2 3 4 5 6 7 Next >>